MetaCap

Immuneering Corporation Class A (IMRX)

NASDAQ: IMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.38-0.07 (-2.03%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMRX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$218.90M
EPS (TTM)
-$0.92
52-week range
3.29 – 8.48
Day range
3.29 – 3.54
Volume / Avg
1.45M / 747.66K
Beta
—

52-week range

$3.29$8.48

IMRX stock today

Immuneering (IMRX) closed at $3.38 on Nov 20, down 2.03% (-$0.07), versus the S&P 500's 3.70% decline. At this level, IMRX sits near the bottom of its 52-week range of $3.29 to $8.48: 60.1% below the high, set on Jan 7, 2026 and 2.8% above the low. IMRX is down 48.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.7%.

Immuneering has posted a net loss over the last twelve months (EPS of -$0.92), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immuneering

Company profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Headquarters
Cambridge, MA
Employees
65
IPO year
2021

Financial highlights

Full financials

Immuneering reported a net loss of $56.0 million, compared with a loss of $61.0 million a year earlier. Diluted earnings per share came in at -$1.27.

Immuneering annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue——$0$316.95K$2.08M
Growth——-100.00%-84.76%-10.02%
Net income$-56.02M$-61.04M$-53.47M$-50.51M$-33.54M
EPS (diluted)$-1.27$-2.04$-1.88$-1.91$-2.46

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$17.00+402.96%

  • Strong buy 2
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.37 vs $-0.29
Surprise
-27.59%

IMRX news

All IMRX news

Immuneering peers

Health Care sector
IMRX peer companies
CompanyPrice% ChgMarket capCompare
RCKTRocket Pharmaceuticals Inc.1.95-7.58%$217.74Mvs IMRX
KROSKeros Therapeutics Inc.11.08-2.72%$217.44Mvs IMRX
PYXSPyxis Oncology Inc.1.81+7.74%$216.49Mvs IMRX
ENTAEnanta Pharmaceuticals Inc.7.62-4.51%$222.19Mvs IMRX
ARCTArcturus Therapeutics Holdings Inc.7.45-1.97%$214.73Mvs IMRX
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs IMRX
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs IMRX
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs IMRX

Indexes, lists and sector

Immuneering stock FAQ

What is Immuneering's stock price today?

IMRX last traded at $3.38 as of Nov 20, 4:00 PM EST, down 2.03% on the day. Prices are delayed at least 15 minutes.

Who is Immuneering's CEO?

Dr. Benjamin J. Zeskind M.B.A., Ph.D. is the chief executive officer of Immuneering Corporation Class A, which has about 65 employees.

What is the IMRX 52-week high?

The 52-week high for IMRX is $8.48 and the 52-week low is $3.29. The stock is currently 60.1% below its high.

Compare IMRX